Antimicrobial Strategies for Cystic Fibrosis

Abstract

Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with Pseudomonas aeruginosa, other important pathogens causing lung inflammation and deterioration exist and should be treated despite the evidence gap. In this chapter, we describe the approaches to the antimicrobial treatment of the most important pathogens in CF and the evidence behind.

The criteria for chronic rhinosinusitis in children with cystic fibrosis are rarely fulfilled after initiation of CFTR modulator treatment

“…A decreased sense of smell has been proven to affect QoL and lower BMI, and pwCF are known to have reduced BMI [13,23]. Our normal olfaction result contrasts the study conducted by Lindig et al in 2012, where pwCF were shown to have reduced olfaction [8].…”